Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BIO 2019 Notebook: Sharpless On Pricing, Takeda M&A Strategy, FDA Cell And Gene Therapy Staffing

Jun 05 2019

• By Sue Sutter and Joseph Haas

Bio 2019 Notebook for Scrip

Related Content

US FDA's Biologics Center Director Expects It Soon Will See 'Growth Spurt'

Jul 02 2018

Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers

Jan 16 2019

BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT

Jun 04 2019

Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?

Jan 10 2017

Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?

Sep 27 2018

Takeda Grabs Shire At Last After Long Pursuit

May 08 2018

Takeda Secures TiGenix But Investor Shire Concerns Bubble Up

Jun 08 2018

It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug

May 24 2019

Related Companies

Novartis AG

Takeda Pharmaceutical Co. Ltd.

ARIAD Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Pricing Debate M & A Gene Therapy Business Strategies FDA Drug Review BioPharmaceutical

More from Drug Pricing

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window